From NEJM Journal Watch (5/8/20): A New First-Line Treatment Regimen for H. pylori Infection

In this industry-funded, phase III trial conducted in the U.S., 455 H. pylori-treatment–naive patients with dyspepsia and a confirmed H. pylori diagnosis were randomized to treatment with capsules containing rifabutin, amoxicillin, and omeprazole or capsules containing amoxicillin and omeprazole for 14 days. Participants took 4 capsules every 8 hours. The eradication rate in the rifabutin-based therapy group was significantly higher (84%) compared with the comparison group (58%). In patients with confirmed adherence to treatment, the eradication rates were 90% versus 65%, respectively. No H. pylori resistance to rifabutin was detected, and side effects were similar between groups.

My take: More treatment options are needed due to drug resistance.  Also, “further studies are needed to compare this new triple therapy with current quadruple therapies.”

Related blog posts:

• Quadruple Therapy for Helicobacter Pylori Favored in Toronto Guidelines
• ACG Guideline for Helicobacter Pylori | gutsandgrowth
• It is Getting Harder to Treat H pylori -Here’s Why
• Helicobacter pylori –useful advice
• Understanding Resistance to Helicobacter pylori | gutsandgrowth
• Salvage Therapy and Standard Therapy for H pylori | gutsandgrowth
• High Rates of Helicobacter Pylori Resistance | gutsandgrowth
• What is evidence-based medicine for H pylori? gutsandgrowth
• H pylori –useful advice gutsandgrowth
• Twyman’s Law | gutsandgrowth